ObesityPILLARNCT07055607

A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice

An observational study of Obesity, run by Novo Nordisk A/S at 30 sites in 3 countries.

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts

Official record

Search all trials

Trial summary

Who is it for?: Ages 18 years and older
Conditions the study is for: Obesity
What is being tested?: Semaglutide
How many people: 1,250 participants
Where: 30 sitesin 3 countries
Study dates: 1 May 2025to 15 Aug 2028
Phase: Observational
Are there results?: Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
No healthy volunteers
Adult, Older adult

Study population: Participants will be treated with Wegovy according to the local labels in Spain, Switzerland and the United Kingdom (UK).

Who may be able to join

Signed consent obtained before any study-related activities (study-related activities are any pro-cedure related to recording of data according to the protocol).
Are eligible for Wegovy and are due to initiate treatment for the first time within the study period; the decision to initiate treatment with commercially available Wegovy has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
Male or female, age above or equal to 18 years at time of signing informed consent.
Have at least one reported weight measurement documented at baseline or within 28 days prior to baseline.
Participants must be able to complete the electronic patient reported outcome (ePRO) questionnaires on a compatible electronic device with internet access.
Fulfil the respective reimbursement criteria in the visit prior to / at baseline in Switzerland and United Kingdom (UK).

Who cannot join

Previous participation in this study. Participation is defined as having given informed consent in this study.
Presence of a documented refusal or unwillingness to participate in research.
Previous treatment with other obesity management pharmacotherapy or any glucagon like pep-tide-1 (GLP- 1) receptor agonist up to 90 days prior to baseline in Switzerland and UK.
Previous treatment with other obesity management pharmacotherapy or any GLP- 1 receptor agonist up to 30 days prior to baseline in Spain.
Pregnant or women of childbearing potential and not using a highly effective contraceptive method.
Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation with the study requirements.

Show all 12Show fewer

Individuals who have reported plans to move out in the next 12 months to an area not serviced by their current site.
Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) in Spain and UK.
Participant has had a prior serious allergic reaction to semaglutide or any of the ingredients in Wegovy.
Have had Saxenda reimbursed by basic mandatory health insurance for a cumulative period of more than 12 months prior to baseline in Switzerland.
Documented history of diabetes mellitus type 1 and type 2 in Spain.
Presence of diabetic complications and/or at risk of hypoglycaemia (with a documented history of frequent hypoglycaemia) in Spain.

Trial locations and contacts

30 sites in 3 countries. Contact the study team or a site near you to ask about taking part.

Country

City, postcode or hospital

30 sites in 3 countries

Spain15 sites

CAP Sarrià
Barcelona, 08017
CAP Sants
Barcelona, 08028
Hospital Vall d'Hebron
Barcelona, 08035
Centro de Salud Cartagena Casco Antiguo
Cartagena, 30201
Hospital Vithas Sevilla
Castilleja de la Cuesta, 41950
Hospital Univ. Virgen de la Arrixaca
El Palmar (Murcia), 30120
Clínica de Endocrinología y Nutrición Dr. Bellido
Ferrol, 15401
Ginegetafe S.L.
Getafe (Madrid), 28901
Centro de Salud La Cuesta
La Cuesta (Santa Cruz de Tenerife), 38320
Hospital Univ. de Gran Canaria Doctor Negrín
Las Palmas de Gran Canaria, 35010
Hospital Universitario Sanitas Virgen del Mar
Madrid, 28016
Hospital Quirónsalud Málaga
Málaga, 29004
Hospital Univ. Central de Asturias
Oviedo, 33011
Hospital Son Espases
Palma de Mallorca, 07120
Hospiten Roca_Ginecología
San Bartolomé de Tirajana (Las Palmas), 35100

Other trials in Spain

Switzerland9 sites

Praxis Dr. Schäfer, Bern
Bern, 3013
Hôpitaux Universitaires de Genève HUG
Geneva, 1211
Luzerner Kantonsspital
Lucerne, 6004
Clinica Moncucco
Lugano, 6900
Centre médical de l'obésité et du diabète
Neuchâtel, 2000
Kantonsspital Olten
Olten, 4600
Praxis Prof. Dr. med. G. Rudofsky
Olten, 4600
Stoffwechselzentrum St. Gallen
Sankt Gallen, 9016
Universitätsspital Zürich
Zurich, 8091

Other trials in Switzerland

United Kingdom6 sites

Barnsley Hospital
Barnsley, S75 2EP
Hull Royal Infirmary
Hull, HU3 2JZ
St Thomas' Hospital - Diabetes
London, SE1 7EH
Luton and Dunstable University Hospital
Luton, LU4 0DZ
St George's Hospital
Tooting, SW17 0RE
Sandwell Health Campus
West Bromwich, West Midlands, B71 4HJ

Other trials in United Kingdom

About this study

This observational study will explore how Wegovy® (Semaglutide) is used in everyday situations, how it might affect things like weight, body mass index (BMI) and waist circumference, and what kind of impact it could have on overall quality of life. The overall purpose of this study is to understand how Wegovy impacts weight when used as part of regular medical care. Participants will be treated with Wegovy as prescribed to the participant by their doctor, in accordance with normal clinical practice. The study will last for about two years.

Conditions: Obesity
Being tested: Semaglutide
Medical subject headings: Obesity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

SemaglutideDrug
Also called Wegovy®
Participants will be treated with commercially available Wegovy according to routine clinical practice and is purely at the discretion of the treating physician. Only individuals receiving Wegovy reimbursed by the healthcare system in their respective countries are included in the study.

Study groups in NCT07055607
Study group	Role	What they receive
Wegovy®		Participants will be treated with Wegovy according to the local labels in Spain, Switzerland and the United Kingdom (UK). Receives: Drug: Semaglutide

What is being measured

The primary outcome is the main question the study is designed to answer.

Absolute change in body weight (kilograms [kg])
Measured in kg.
Measured: From baseline (0 months) to the end of observation (24 months)
Percentage change in body weight (percentage [%])
Measured in %.
Measured: From baseline (0 months) to the end of observation (24 months)

Secondary outcomes (45)

Absolute change in waist circumference (centimeters [cm])
Measured in cm.
Measured: From baseline (0 months) to the end of observation (24 months)
Absolute change in waist-to-height ratio
Measured as ratio.
Measured: From baseline (0 months) to the end of observation (24 months)
Percentage change in waist circumference (%)
Measured in %.
Measured: From baseline (0 months) to the end of observation (24 months)
Number of participants who achieve greater than or equal to (>=) 5 percent body weight reduction (Yes/No)
Measured as count of participants.
Measured: From baseline (0 months) to the end of observation (24 months)
For Switzerland: Number of participants who achieve >=7 percent body weight reduction (Yes/No)
Measured as count of participants.
Measured: From baseline (0 months) to the end of observation (22 months)
Number of participants who achieve >=10 percent body weight reduction (Yes/No)
Measured as count of participants.
Measured: From baseline (0 months) to the end of observation (24 months)
For Switzerland: Number of participants who achieve >=12 percent body weight reduction (Yes/No)
Measured as count of participants.
Measured: From baseline (0 months) to the end of observation (22 months)
Number of participants who achieve >=15 percent body weight reduction (Yes/No)
Measured as count of participants.
Measured: From baseline (0 months) to the end of observation (24 months)
Number of participants who achieve >=20 percent body weight reduction (Yes/No)
Measured as count of participants.
Measured: From baseline (0 months) to the end of observation (24 months)
Change in percentage of participant in each Body Mass Index (BMI) category
Measured as count of participants.
Measured: From baseline (0 months) to the end of observation (24 months)
Change in High Density Lipoprotein (HDL) Cholesterol (milligrams per decilitre [mg/dL])
Measured in mg/dL.
Measured: From baseline (0 months) to the end of observation (24 months)
Change in HDL Cholesterol (millimoles per litre [mmol/L])
Measured in mmol/L.
Measured: From baseline (0 months) to the end of observation (24 months)
Change in Low Density Lipoprotein (LDL) Cholesterol (mg/dL)
Measured in mg/dL.
Measured: From baseline (0 months) to the end of observation (24 months)
Change in LDL Cholesterol (mmol/L)
Measured in mmol/L.
Measured: From baseline (0 months) to the end of observation (24 months)
Change in Very Low Density Lipoprotein (VLDL) Cholesterol (mg/dL)
Measured in mg/dL.
Measured: From baseline (0 months) to the end of observation (24 months)
Change in VLDL Cholesterol (mmol/L)
Measured in mmol/L.
Measured: From baseline (0 months) to the end of observation (24 months)
Change in Free Fatty Acid (FFA) (mmol/L)
Measured in mmol/L.
Measured: From baseline (0 months) to the end of observation (24 months)
Change in Triglycerides (mg/dL)
Measured in mg/dL.
Measured: From baseline (0 months) to the end of observation (24 months)
Change in Triglycerides (mmol/L)
Measured in mmol/L.
Measured: From baseline (0 months) to the end of observation (24 months)
Change in Glycated Haemoglobin (HbA1c) (%)
Measured in %.
Measured: From baseline (0 months) to the end of observation (24 months)
Change in systolic blood pressure
Measured in millimeter of mercury (mmHg).
Measured: From baseline (0 months) to the end of observation (24 months)
Change in diastolic blood pressure
Measured in mmHg.
Measured: From baseline (0 months) to the end of observation (24 months)
Percentage change in the prevalence of obesity-related conditions
Obesity-related conditions will be assessed as Yes/No in the following categories: Myocardial infarction (MI), Stroke, Heart failure with reduced Ejection Fraction (HFrEF) and Heart Failure with preserved Ejection Fraction (HFpEF), Atherosclerotic cardiovascular disease (ASCVD) defined as at least one of coronary artery disease, peripheral artery disease, cerebrovascular disease and atherosclerosis, Metabolic dysfunction-associated steatotic liver disease (MASLD), Metabolic dysfunction-associated steatohepatitis (MASH), Chronic kidney disease (CKD), Obstructive sleep apnoea, Poly-cystic ovary syndrome (PCOS), Infertility, Urinary incontinence, Lower back pain, Knee / hip oste-oarthritis, Musculoskeletal pain, Asthma, Chronic Obstructive Pulmonary Disease (COPD), Clini-cian-diagnosed mood disorder, Clinician-diagnosed eating disorder.
Measured: From baseline (0 months) to the end of observation (24 months)
Percentage change in the total daily dosage of concomitant drugs (Yes/No)
Total daily dosage of concomitant drugs were assessed as Yes/No among the following: Antidiabetic medication, Antihypertensive medication, Lipid-lowering medication, Pain medica-tion, Psychotropic medication, Antithrombotic agents, Thyroid hormone medication, Proton pump inhibitor.
Measured: From baseline (0 months) to the end of observation (24 months)
Percentage change in the usage of additional treatments for weight loss (Yes/No)
Usage of additional treatments for weight loss will be assessed as Yes/No among the following: Bariatric surgery, Clinical practice / healthcare-provided diet plan, Alternative diet plan, Exercise regime, Behavioural and alternative therapy, Digital health app.
Measured: From baseline (0 months) to the end of observation (24 months)
Median time to Wegovy® maintenance dose
Measured in weeks.
Measured: From baseline to the date of reported maintenance dose during the observation period (24 months)
Median time to each Wegovy® dose escalation
Measured in weeks.
Measured: Date from the start of the previous dose to the date of each subsequent escalation during the observation period (24 months)
Maximum dose of Wegovy® for weight management
Measured in milligrams (mg).
Measured: After baseline to any given time during the observation period (24 months)
For UK and Spain: Change in percentage of participants on Wegovy® with each of drug-related adverse reaction
Measured as percentage of participants.
Measured: From baseline (0 months) to the end of observation (24 months)
Median persistence time of Wegovy® treatment
Measured in weeks.
Measured: From baseline (0 months) to the end of observation (24 months)
Change in percentage of participants who discontinued
Measured as percentage of participants.
Measured: From baseline (0 months) to the end of observation (24 months)
Percentage of participants who discontinued/withdrawn
Measured as percentage of participants. Reason for discountinued/withdrawn due to Lack of efficacy as per reimbursement criteria (UK, CH only), Lack of efficacy as per clinical judgment, Lack of efficacy as per subject's judgment, Non-serious gastro intestinal event (nausea, vomiting, diarrhea, constipation and/or abdominal pain), Adverse reaction ((AR) not otherwise specified in the listed reasons), Patient's request, Pregnancy,Financial constraints (cost of medication, change in eligibility for reimbursement) (CH and ES only), Reaching a BMI of less than (<) 25 kilograms per meter square (kg/m^2), death and other.
Measured: From baseline (0 months) to the end of observation (24 months)
For Switzerland: Percentage of participants who continued under reimbursement by basic mandatory health insurance (Yes/No)
Measured as percentage of participants.
Measured: From baseline (0 months) to the end of observation (22 months)
For Switzerland: Percentage of participants who switched to out-of-pocket payment (or any other arrangement) (Yes/No)
Measured as percentage of participants.
Measured: From baseline (0 months) to the end of observation (22 months)
For Switzerland: Percentage of participants who stopped treatment (Yes/No)
Measured as percentage of participants.
Measured: From baseline (0 months) to the end of observation (22 months)
For Spain: Percentage of participants who have continued under out-of-pocket payment (Yes/No)
Measured as percentage of participants.
Measured: From baseline (0 months) to the end of observation (12 months)
For Spain: Percentage of participants who have switched to reimbursement by the Public Health System (Yes/No)
Measured as percentage of participants.
Measured: From baseline (0 months) to the end of observation (12 months)
For Switzerland: Change in percentage of participants fulfilling the necessary weight loss reimbursement criteria
Measured as percentage of participants.
Measured: From baseline (0 months) to the end of observation (22 months)
Absolute change in the EuroQoL-5-Dimension (5-Level) (EQ-5D-5L)
EQ-5D-5L consists of 2 components, EQ-5D descriptive system and EQ visual analogue scale (EQ-VAS). EQ-5D 5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension will have 5 levels: no, slight, moderate, severe and extreme problems. Respondent is asked to indicate the health state by ticking the box next to the most appropriate statement in each of the five dimensions. Decision will result in a 1-digit number that expresses the level for that dimension. Digits for five dimensions can be combined into a 5-digit number that describes patient's health state. EQ-5D health states can be converted into a single summary number (index value) which will reflect how good/bad a health state is according to valuation set in general population of a country/region. Index score records an average health status according to dimensions using an algorithm,ranges 0-1 with higher score indicating better health status.
Measured: From baseline (0 months) to the end of observation (24 months)
Absolute change in the EQ Visual Analogue Score (EQ-VAS)
Measured as score points. The EQ-VAS will record the respondent's self-rated health on a vertical visual analogue scale. The scale is numbered from 0 to 100, with lower score indicating worst health and higher score indicating best health.
Measured: From baseline (0 months) to the end of observation (24 months)
Absolute change in the Adelphi Adherence Questionnaire (ADAQ) score
Measured as score points. ADAQ is an 11-item instrument that measures adherence to medication. The instrument includes 4 items that assess adherence behaviours and 7 items that assess drivers of non adherence. Each item yields a score ranging from 0 to 4 and item scores are then averaged to produce the ADAQ score. The ADAQ score is a measure of medication adherence ranging from 0 to 4, with lower scores representing greater adherence.
Measured: From baseline (0 months) to the end of observation (24 months)
Absolute change in treatment satisfaction questionnaire for medication 9 (TSQM-9) domain scores
Measured as score points. TSQM-9 is a 9-item instrument that measures a patient's satisfaction with their medication. The instrument assesses three domains: effectiveness, convenience and global satisfaction. Each domain will produce a score ranging from 0 to 100, with higher scores reflecting higher satisfaction on that domain.
Measured: From baseline (0 months) to the end of observation (24 months)
Absolute change in percentage of work time missed (absenteeism) due to weight problem using Work Productivity and Activity Impairment Questionnaire (WPAI)
Measured as score points. WPAI is a self-administered instrument used to assess the impact of disease on work productivity and regular activities during the past seven days. WPAI outcomes are expressed as impairment percentages (0-100), with higher numbers indicating greater impairment and less productivity, that is, worse outcomes.
Measured: From baseline (0 months) to the end of observation (24 months)
Absolute change in percentage of time impaired while working (presenteeism) due to weight problem using WPAI
Measured as score points. WPAI is a self-administered instrument used to assess the impact of disease on work productivity and regular activities during the past seven days. WPAI outcomes are expressed as impairment percentages (0-100), with higher numbers indicating greater impairment and less productivity, that is, worse outcomes.
Measured: From baseline (0 months) to the end of observation (24 months)
Absolute change in percentage of activity impairment due to weight problem using WPAI
Measured as score points. WPAI is a self-administered instrument used to assess the impact of disease on work productivity and regular activities during the past seven days. WPAI outcomes are expressed as impairment percentages (0-100), with higher numbers indicating greater impairment and less productivity, that is, worse outcomes.
Measured: From baseline (0 months) to the end of observation (24 months)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

1 May 202515 Aug 2028

First posted9 Jul 2025
Study start1 May 2025
Primary completion15 Aug 2028 (estimated)
Study completion15 Aug 2028 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for ObesityStudies of the same condition, open and under way.
More trials run by Novo Nordisk A/SThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Observational
Observational model: Case only
Time perspective: Prospective
Enrolment: 1,250 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT07055607
Sponsor's protocol ID: NN9536-8189
Other IDs: U1111-1308-1428
Acronym: PILLAR
Status last verified: Aug 2026
First submitted: 13 Jun 2025
Last updated: 4 Aug 2026
Results posted: No
Data monitoring committee: No
Individual data sharing: Yes: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.

Interested in taking part?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See sites and contacts

RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)

All Obesity trials

Study at a glance

From the registry record, last updated by the sponsor on 4 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice
ClinicalTrials.gov ID: NCT07055607
Acronym / sponsor ID: PILLAR / NN9536-8189
Conditions: Obesity
Study type: Observational
Recruitment status: Enrolling by invitation
Enrolment: 1,250 participants (estimated)
Lead sponsor: Novo Nordisk A/SIndustry (pharma, biotech, devices)
Study start: 1 May 2025 (actual)
Primary completion: 15 Aug 2028 (estimated)
Study completion: 15 Aug 2028 (estimated)
First posted: 9 Jul 2025 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Observational model: Case only
Time perspective: Prospective
Number of arms: 1

Arm	Type	Receives
Wegovy®	–	Drug: SemaglutideParticipants will be treated with Wegovy according to the local labels in Spain, Switzerland and the United Kingdom (UK).

Who may qualify

Ages: 18 years and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult
Study population: Participants will be treated with Wegovy according to the local labels in Spain, Switzerland and the United Kingdom (UK).

Key inclusion criteria (6 listed)

Signed consent obtained before any study-related activities (study-related activities are any pro-cedure related to recording of data according to the protocol).
Are eligible for Wegovy and are due to initiate treatment for the first time within the study period; the decision to initiate treatment with commercially available Wegovy has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
Male or female, age above or equal to 18 years at time of signing informed consent.
Have at least one reported weight measurement documented at baseline or within 28 days prior to baseline.
Participants must be able to complete the electronic patient reported outcome (ePRO) questionnaires on a compatible electronic device with internet access.

Key exclusion criteria (12 listed)

Previous participation in this study. Participation is defined as having given informed consent in this study.
Presence of a documented refusal or unwillingness to participate in research.
Previous treatment with other obesity management pharmacotherapy or any glucagon like pep-tide-1 (GLP- 1) receptor agonist up to 90 days prior to baseline in Switzerland and UK.
Previous treatment with other obesity management pharmacotherapy or any GLP- 1 receptor agonist up to 30 days prior to baseline in Spain.
Pregnant or women of childbearing potential and not using a highly effective contraceptive method.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
SemaglutideAlso: Wegovy®Participants will be treated with commercially available Wegovy according to routine clinical practice and is purely at the discretion of the treating physician. Only individuals receiving Wegovy reimbursed by the healthcare system in their respective countries are included in the study.	Drug	Wegovy®

Primary outcome

Absolute change in body weight (kilograms [kg])
Time frame: From baseline (0 months) to the end of observation (24 months)
Measured in kg.
Percentage change in body weight (percentage [%])
Time frame: From baseline (0 months) to the end of observation (24 months)
Measured in %.

45 secondary outcomes

Absolute change in waist circumference (centimeters [cm])
Time frame: From baseline (0 months) to the end of observation (24 months)
Absolute change in waist-to-height ratio
Time frame: From baseline (0 months) to the end of observation (24 months)
Percentage change in waist circumference (%)
Time frame: From baseline (0 months) to the end of observation (24 months)
Number of participants who achieve greater than or equal to (>=) 5 percent body weight reduction (Yes/No)
Time frame: From baseline (0 months) to the end of observation (24 months)
For Switzerland: Number of participants who achieve >=7 percent body weight reduction (Yes/No)
Time frame: From baseline (0 months) to the end of observation (22 months)
Number of participants who achieve >=10 percent body weight reduction (Yes/No)
Time frame: From baseline (0 months) to the end of observation (24 months)
For Switzerland: Number of participants who achieve >=12 percent body weight reduction (Yes/No)
Time frame: From baseline (0 months) to the end of observation (22 months)
Number of participants who achieve >=15 percent body weight reduction (Yes/No)
Time frame: From baseline (0 months) to the end of observation (24 months)
Number of participants who achieve >=20 percent body weight reduction (Yes/No)
Time frame: From baseline (0 months) to the end of observation (24 months)
Change in percentage of participant in each Body Mass Index (BMI) category
Time frame: From baseline (0 months) to the end of observation (24 months)
Change in High Density Lipoprotein (HDL) Cholesterol (milligrams per decilitre [mg/dL])
Time frame: From baseline (0 months) to the end of observation (24 months)
Change in HDL Cholesterol (millimoles per litre [mmol/L])
Time frame: From baseline (0 months) to the end of observation (24 months)
Change in Low Density Lipoprotein (LDL) Cholesterol (mg/dL)
Time frame: From baseline (0 months) to the end of observation (24 months)
Change in LDL Cholesterol (mmol/L)
Time frame: From baseline (0 months) to the end of observation (24 months)
Change in Very Low Density Lipoprotein (VLDL) Cholesterol (mg/dL)
Time frame: From baseline (0 months) to the end of observation (24 months)
Change in VLDL Cholesterol (mmol/L)
Time frame: From baseline (0 months) to the end of observation (24 months)
Change in Free Fatty Acid (FFA) (mmol/L)
Time frame: From baseline (0 months) to the end of observation (24 months)
Change in Triglycerides (mg/dL)
Time frame: From baseline (0 months) to the end of observation (24 months)
Change in Triglycerides (mmol/L)
Time frame: From baseline (0 months) to the end of observation (24 months)
Change in Glycated Haemoglobin (HbA1c) (%)
Time frame: From baseline (0 months) to the end of observation (24 months)
Change in systolic blood pressure
Time frame: From baseline (0 months) to the end of observation (24 months)
Change in diastolic blood pressure
Time frame: From baseline (0 months) to the end of observation (24 months)
Percentage change in the prevalence of obesity-related conditions
Time frame: From baseline (0 months) to the end of observation (24 months)
Percentage change in the total daily dosage of concomitant drugs (Yes/No)
Time frame: From baseline (0 months) to the end of observation (24 months)
Percentage change in the usage of additional treatments for weight loss (Yes/No)
Time frame: From baseline (0 months) to the end of observation (24 months)
Median time to Wegovy® maintenance dose
Time frame: From baseline to the date of reported maintenance dose during the observation period (24 months)
Median time to each Wegovy® dose escalation
Time frame: Date from the start of the previous dose to the date of each subsequent escalation during the observation period (24 months)
Maximum dose of Wegovy® for weight management
Time frame: After baseline to any given time during the observation period (24 months)
For UK and Spain: Change in percentage of participants on Wegovy® with each of drug-related adverse reaction
Time frame: From baseline (0 months) to the end of observation (24 months)
Median persistence time of Wegovy® treatment
Time frame: From baseline (0 months) to the end of observation (24 months)
Change in percentage of participants who discontinued
Time frame: From baseline (0 months) to the end of observation (24 months)
Percentage of participants who discontinued/withdrawn
Time frame: From baseline (0 months) to the end of observation (24 months)
For Switzerland: Percentage of participants who continued under reimbursement by basic mandatory health insurance (Yes/No)
Time frame: From baseline (0 months) to the end of observation (22 months)
For Switzerland: Percentage of participants who switched to out-of-pocket payment (or any other arrangement) (Yes/No)
Time frame: From baseline (0 months) to the end of observation (22 months)
For Switzerland: Percentage of participants who stopped treatment (Yes/No)
Time frame: From baseline (0 months) to the end of observation (22 months)
For Spain: Percentage of participants who have continued under out-of-pocket payment (Yes/No)
Time frame: From baseline (0 months) to the end of observation (12 months)
For Spain: Percentage of participants who have switched to reimbursement by the Public Health System (Yes/No)
Time frame: From baseline (0 months) to the end of observation (12 months)
For Switzerland: Change in percentage of participants fulfilling the necessary weight loss reimbursement criteria
Time frame: From baseline (0 months) to the end of observation (22 months)
Absolute change in the EuroQoL-5-Dimension (5-Level) (EQ-5D-5L)
Time frame: From baseline (0 months) to the end of observation (24 months)
Absolute change in the EQ Visual Analogue Score (EQ-VAS)
Time frame: From baseline (0 months) to the end of observation (24 months)

Results and safety

This study is still under way. Results are not available in the source record yet.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 4 Aug 2026.
Individual participant dataSharing planned: Yes. According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.

Related trials for Obesity

RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.

Clinical Transparency (dept. 2834) study director

Novo Nordisk A/S

30 sites in 3 countries: see every site and its status.

Questions about this trial

What is this clinical trial studying?

An observational study of Obesity, run by Novo Nordisk A/S at 30 sites in 3 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: enrolling by invitation, as of the sponsor's last update on 4 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 30 sites in Spain, Switzerland, United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Absolute change in body weight (kilograms [kg]) (time frame: From baseline (0 months) to the end of observation (24 months)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07055607.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Aug 2026.